 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Real-world assessment of the long-term efficacy of first-line pembrolizumab monotherapy in advanced NSCLC patients with PD-L1 ≥ 50%

Front Oncol: Real-world assessment of the long-term efficacy of first-line pembrolizumab monotherapy in advanced NSCLC patients with PD-L1 ≥ 50%

 Last Update: 2022-04-23
 Source: Internet
 Author: User

Tags

1 2 3 trichloropropane

50 times 24

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Frontiers in Oncology published a real-world study from the United States, mainly evaluating the long-term efficacy of first-line pembrolizumab (pembrolizumab) monotherapy in patients with advanced NSCLC
with PD-L1 ≥ 50% .

NSCLC

The study included two cohorts of patients: the electronic medical record cohort (EHR cohort) and the manual review cohort (spotlight cohort), and assessed overall survival (OS) in the two cohorts, and real-world progression-free survival (rwPFS) in the spotlight cohort and real-world Tumor Response (rwTR)
.

The EHR cohort included 566 patients (298 [53%] men); whereas the spotlight cohort included 228 patients (105 [46%] men); the median age of patients in both groups was 71 years
.

The median follow-up time in the EHR and spotlight cohorts was 35.
1 months (range 12.
0-52.
7) and 38.
4 months (range 33.
1-44.
9), respectively
.

The median OS was 19.

The median follow-up time in the EHR and spotlight cohorts was 35.

Of the 182 (32%) patients in the EHR cohort who received second-line systemic therapy, most commonly platinum-based chemotherapy or immunotherapy (ICI monotherapy or ICI-chemotherapy), 63 (35%) patients received third-line therapy treatment, and 16/63 (25%) patients received fourth-line therapy
.

In the spotlight cohort, 87 (38%) patients received second-line therapy, of which 26 (30%) received third-line therapy; 7 were fourth-line therapy, and 3 were fifth-line therapy

For the spotlight cohort, the median rwPFS was 7.
3 months (95% CI, 5.
7 9.
2)
.

For the spotlight cohort, the median rwPFS was 7.

In the spotlight cohort, a total of 17 patients (7%) had an rwTR assessment of CR, 71 patients (31%) had a PR assessment of PR, and the rwTRR was 38.
6% (95% CI, 32.
2-45.
2) for a total of 122 patients ( 54%) disease control (CR + PR + stable disease)
.

In the spotlight cohort, a total of 17 patients (7%) had an rwTR assessment of CR, 71 patients (31%) had a PR assessment of PR, and the rwTRR was 38.

For 151 of 228 patients (66%) who discontinued pembrolizumab, the most common reasons were disease progression (70 [46%]) and treatment-related adverse reactions (35 [23%])
.

No serious adverse reactions were found

For 151 of 228 patients (66%) who discontinued pembrolizumab, the most common reasons were disease progression (70 [46%]) and treatment-related adverse reactions (35 [23%])

In conclusion, the study shows that for patients with advanced NSCLC with PD-L1≧50%, the real-world efficacy of first-line pembrolizumab (pembrolizumab) monotherapy is consistent with clinical studies, which supports the application of this regimen
.
Studies have shown that for patients with advanced NSCLC with PD-L1≧50%, the real-world efficacy of first-line pembrolizumab (pembrolizumab) monotherapy is consistent with clinical studies, supporting the application of this regimen
.
Studies have shown that for patients with advanced NSCLC with PD-L1≧50%, the real-world efficacy of first-line pembrolizumab (pembrolizumab) monotherapy is consistent with clinical studies, supporting the application of this regimen
.

Original source:

Velcheti V, Hu X, Yang L, Pietanza MC and Burke T (2022) Long-Term RealWorld Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.
Front .
Oncol.
12:834761.
doi: 10.
3389/fonc.
2022.
834761

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.